A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®

The purpose of this study is to investigate real practices of treatment with Symbicort Turbuhaler for 3 months in asthma and patient compliance.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

6 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Hefel, Anhui, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Provision of informed consent
Asthmatics who has been prescribed Symbicort according to physician's judgement
Usage of Symbicort should follow local prescribing information

Exclusion criteria

Not being involved in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
No previous enrolment in the present study

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Acronym: Symb NIS

Important dates

Study start: 2007
Study completion: 2007
First posted: Sep 21, 2007
Registry last updated: Jun 9, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed